American Journal of Cancer Prevention
ISSN (Print): 2328-7314 ISSN (Online): 2328-7322 Website: Editor-in-chief: Nabil Abdel-Hamid
Open Access
Journal Browser
American Journal of Cancer Prevention. 2015, 3(1), 19-22
DOI: 10.12691/ajcp-3-1-5
Open AccessArticle

Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran

Mehrdad Payandeh1, Masoud Sadeghi2, 3, , Edris Sadeghi2, 3 and Faezeh Gholami2

1Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

3Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Pub. Date: March 13, 2015

Cite this paper:
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi and Faezeh Gholami. Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. American Journal of Cancer Prevention. 2015; 3(1):19-22. doi: 10.12691/ajcp-3-1-5


Background: KRAS/NRAS/BRAF mutations are useful markers for predicting responses to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. The aim of this study was to investigate the clinicopathological characteristics and distribution by tumor localization of KRAS mutations in metastatic colorectal cancer and analysis of NRAS and BRAF in the patients in Western Iran. Materials and Methods: Between May 2008 and November 2014, Thirty- three patients with metastatic or high risk CRC were included in our study. DNA was extracted by FFPE QIAGEN Kit and also KRAS/NRAS and BRAF V600E were analyzed using allele specific PCR primers and pyrosequencing. The overall survival for patients was plotted by GraphPad Prism 5 software. Results: The mean of age for patients at diagnosis was 57.67±13.20 years (range, 28-80 years), 19 patients (57.6%) were male. Of 33 patients, 9 patients (27.3%) were high risk and rest of patients had metastasis that metastasis was more to liver and lung, respectively. Of 33 patients, 21 patients (63.6%) have KRAS wild-type and 12 patients (27.3%) have KRAS mutation. Also, 5 samples of patients were checked for BRAF and NRAS. The mean overall survival for patients with metastatic colorectal cancer was 20 months. Location of tumor in 32 patients with metastatic colorectal cancer was left-side colon. Conclusions: NRAS/BRAF testing should be used together and with KRAS genotype to select patients who will likely benefit from anti-EGFR therapy and also location of tumor probably in patients with metastatic colorectal cancer in western Iran is more on left-side colon that it needs other studies with greater volume of patients.

KRAS NRAS overall survival colorectal cancer

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013. 63 (1): 11-30.
[2]  Perincheri S, Hui P. KRAS mutation testing in clinical practice. Expert Rev Mol Diagn. 2014. 1-10.
[3]  Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem. 2012. 12 (2): 163-71.
[4]  André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013. 24 (2): 412-9.
[5]  Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013. 369 (11): 1023-34.
[6]  Stintzing S, Stremitzer S, Sebio A, Lenz HJ. Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC): Personalized Medicine at Work. Hematol Oncol Clin North Am. 2015. 29 (1): 43-60.
[7]  Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015. 136 (1): 83-90.
[8]  Roa I, Sánchez T, Majlis A, Schalper K. [KRAS gene mutation in colorectal cancer]. Rev Med Chil. 2013. 141 (9): 1166-72.
[9]  Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2014.
[10]  Cai B, Wang MY, Liao K, Xu YS, Wei WY, Zhuang Y, et al. Distribution characteristics of 3,369 chinese colorectal cancer patients for gender, age, location and tumor size during colonoscopy. Asian Pac J Cancer Prev. 2014. 15 (20): 8951-5.
[11]  Hajmanoochehri F, Asefzadeh S, Kazemifar AM, Ebtehaj M. Clinicopathological features of colon adenocarcinoma in Qazvin, Iran: a 16 year study. Asian Pac J Cancer Prev. 2014. 15 (2): 951-5.
[12]  Thapa R, Lakhey M, Yadav PK. Clinico-pathological Study of Colorectal Carcinoma. JNMA J Nepal Med Assoc. 2013. 52 (191): 449-52.
[13]  De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol. 2014. 20 (29): 9732-43.
[14]  Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004. 350 (23): 2335-42.
[15]  Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004. 351 (4): 337-45.
[16]  Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Hermans J, Buys CC, et al. Impact of KRAS and TP53 mutations on survival in patients with left-and right-sided Dukes' C colon cancer. Am J Gastroenterol. 2000. 95 (10): 2953-7.
[17]  Zulhabri O, Rahman J, Ismail S, Isa MR, Wan Zurinah WN. Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer. Singapore Med J. 2012. 53 (1): 26-31.
[18]  Zahrani A, Kandil M, Badar T, Abdelsalam M, Al-Faiar A, Ismail A. Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia. Tumori. 2014. 100 (1): 75-9.
[19]  Baskin Y, Dagdeviren YK, Calibasi G, Canda AE, Sarioglu S, Ellidokuz H, et al. KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas. J Gastrointest Oncol. 2014. 5 (4): 265-9.
[20]  Montomoli J, Hamilton-Dutoit SJ, Frøslev T, Taylor A, Erichsen R. Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study. Clin Exp Gastroenterol. 2012. 5: 167-71.
[21]  Sameer AS, Chowdhri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer. 2009. 46 (3): 219-25.
[22]  Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 2009. 219 (4): 435-45.
[23]  Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010. 28 (3): 466-74.
[24]  Watanabe T, Yoshino T, Uetake H, Yamazaki K, Ishiguro M, Kurokawa T, et al. KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol. 2013. 43 (7): 706-12.
[25]  Gunal A, Hui P, Kilic S, Xu R, Jain D, Mitchell K, et al. KRAS mutations are associated with specific morphologic features in colon cancer. J Clin Gastroenterol. 2013. 47 (6): 509-14.
[26]  El-Halabi MM, Chaaban SA, Meouchy J, Page S, Salyers WJ Jr. Colon cancer metastasis to mediastinal lymph nodes without liver or lung involvement: A case report. Oncol Lett. 2014. 8 (5): 2221-2224.
[27]  Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol. 2007. 13 (28): 3806-15.
[28]  Chan WL, Lee VH, Siu WK, Ho PY, Liu RK, Leung TW. Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers. South Asian J Cancer. 2014; 3 (3): 175-8.
[29]  De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008; 19 (3): 508-15.
[30]  Kim ST, Park KH, Kim JS, Shin SW, Kim YH. Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. Cancer Res Treat. 2013; 45 (1): 55-62.
[31]  Bagadi SB, Sanghvi M, Nair SB, Das BR. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers. 2012; 27 (1): 27-33.